131-I-Metaiodobenzylguanidine Treatment of Malignant Phe

131-I-间碘苄基胍治疗恶性 Phe

• 批准号: 7334117
• 负责人: Karel Pacak
• 金额: --
• 依托单位: EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/7334117
• 关键词: 131; Metaiodobenzylguanidine; Treatment; Malignant; Phe

Pheochromocytomas are tumors of chromaffin cells that synthesize and secrete catecholamines. This project tests the efficacy of radiotoxic treatment of malignant pheochromocytoma using 131I-metaiodobenzylguanidine (131I-MIBG), and in particular tests whether pre-treatment using specific drugs (so called sentitizers) increases the efficacy of 131I-MIBG treatment in reducing the size and number of tumors and the tumor burden. The central hypothesis is that in patients with malignant pheochromocytoma, treatment with 131I-MIBG destroys tumor cells and thereby decreases the size and number of tumors and the tumor burden; and that the "sensitization" procedures augment the effectiveness of 131I-MIBG. Recently, the protocol has been approved by the FDA and the contract from the University of Michigan, to obtain 131-I-MIBG for treatment, has been approved. Patients are being enrolled into the study.

嗜铬细胞瘤是合成和分泌儿茶酚胺的染色体细胞的肿瘤。该项目测试了使用131i-Metaiododobenzylguanidine（131i-MiBG）对恶性毒性毒性细胞瘤进行放射性毒性治疗的疗效，特别是测试了使用特定药物（所谓的Sentitizer）进行预处理是否会增加131I-MIBG治疗的功效131I-MIBG对尺寸和数字的尺寸和数量的数字增加了尺寸和数量。中心假设是，在患有恶性嗜铬细胞瘤的患者中，用131i-MIBG治疗会破坏肿瘤细胞，从而减少肿瘤的大小和数量和肿瘤负担。并且“敏化”程序增强了131i-Mibg的有效性。最近，该方案已获得FDA和密歇根大学的合同，以获得131-I-MIBG进行治疗，已获得批准。患者正在研究中。